eMed CEO resigns
In a move that took the PACS industry by surprise, eMed Technologies announced May 17 the resignation of CEO Caren Mason. The company cited Mason’s long-distance commute from Wisconsin to eMed’s Boston-based headquarters and her
In a move that took the PACS industry by surprise, eMed Technologies announced May 17 the resignation of CEO Caren Mason. The company cited Mason’s long-distance commute from Wisconsin to eMed’s Boston-based headquarters and her responsibilities to family as reasons for her resignation. Since taking the helm in January 2000, Mason led eMed to an improved position within the PACS and networking marketplace. She also bolstered corporate finances by securing $22 million dollars in venture capital investment. The company’s board of directors has initiated a search for Mason’s replacement.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
